Sign in
Taking people in United StatesPhase 3

Testing Etavopivat for Pain Crises in Sickle Cell Disease

Tests etavopivat or a placebo in teenagers and adults with sickle cell disease.

Key facts

Who runs it
Novo Nordisk A/S
Where
Atlanta, Aurora, Birmingham, Boston, Brooklyn, Chicago, Cleveland, Columbus, Detroit, Durham, Fairfax, Greenville, Hollywood, Houston, Las Vegas, Little Rock, Los Angeles, Madera, Memphis, Minneapolis, Mobile, Mount Kisco, New Orleans, Newark, Norfolk, Oklahoma City, Omaha, Orange, Palo Alto, Philadelphia, Phoenix, Queens, Richmond, St Louis, Tacoma, The Bronx, Torrance, Washington D.C., Wilmington, and Winston-Salem, United StatesSee the 49 sitesAlso in 20 other countries, 115 sites
Trial code
Registry title
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Status
Recruiting
Phase
Phase 3
People taking part
510 people, planned
Started
17 Feb 2025
Expected to end
12 Aug 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Etavopivat
  • Placebo
Record updated
17 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 12 and older with sickle cell disease who have had several documented pain crises (vaso-occlusive crises) in the past year.

Age
12 years or older
Sex
Men and women
Disease stage
Confirmed sickle cell disease (HbSS, HbSβ0-thalassemia or other sickle cell variants), with 2-15 documented vaso-occlusive crises in the 12 months before screening, and haemoglobin between 5.0 and 10.0 g/dL (50 to 100 g/L).
Earlier treatment
Cannot have used voxelotor or similar medicine within 28 days, a selectin antagonist (such as crizanlizumab) within 28 days or 5 half-lives, or erythropoietin within 28 days. Cannot have had prior cell-based therapy such as a stem cell transplant or gene therapy.
Biomarker or test result
Sickle cell disease genotype (HbSS, HbSβ0-thalassemia or other variants) shown by past or screening lab tests. Haemoglobin 5.0 to 10.0 g/dL.

Main reasons for not taking part

  • Regular scheduled blood transfusions, or 6 or more transfusions in the past 12 months
  • Prior cell-based therapy (stem cell transplant, gene therapy)
  • Liver problems (ALT above 4.0 × ULN or direct bilirubin above 3.0 × ULN)
  • Severe kidney problems or chronic dialysis
  • Walking distance below 100m on the 6-minute walk test at screening

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Male or female
  • Age 12 years or above at the time of signing the informed consent
  • Confirmed diagnosis of sickle cell disease: Documentation of sickle cell disease (SCD) genotype (HbSS, HbSβ0-thalassemia or other sickle cell syndrome variants) based on prior history of laboratory testing or screening test results from central laboratory. Molecular genotyping is not required. SCD genotype may be determined from the results of haemoglobin (Hb) electrophoresis, high-performance liquid chromatography (HPLC) or similar testing. Note that Hb electrophoresis is performed by the central laboratory at screening
  • Have 2-15 episodes of documented vaso occlusive crises (VOC) within the 12 months prior to screening. Documentation must exist in the participant's medical record prior to randomisation. Events based solely on participant recall without supporting documentation should not be counted towards eligibility
  • Hb greater than or equal to (≥) 5.0 and less than or equal to (≤) 10.0 g/dL (greater than or equal to (≥) 50 and less than or equal to (≤) 100 grams per litre [g/L]) at screening

Who cannot take part

  • Use of voxelotor or similar agent within 28 days prior to starting study treatment or anticipated need for this agent during the study
  • Use of a selectin antagonist (e.g., crizanlizumab, monoclonal antibody or small molecule) within 28 days or 5 half-lives (whichever is longer) prior to starting study treatment or anticipated need for such agents during the study
  • Receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) or greater than or equal to 6 transfusion events within the previous 12 months prior to screening (i.e., an average of 1 transfusion event every 60 days)
  • Receiving or use of concomitant medications that are strong or moderate inducers of CYP3A4 (cytochrome p450 3a4) within 2 weeks of starting study treatment or anticipated need for such agents during the study
  • Receipt of prior cellular-based therapy (e.g., haematopoietic cell transplant, gene modification therapy)
  • Participants who have received an RBC transfusion for any reason within 60 days of the screening period or 60 days of the randomisation day are only eligible if HbA (adult haemoglobin) less than 10% by Hb electrophoresis is documented prior to starting study treatment
  • Hepatic dysfunction characterized by:; Alanine aminotransferase (ALT) greater than 4.0 × upper limit of normal (ULN) or; Direct bilirubin greater than 3.0 × ULN
  • Severe renal dysfunction (estimated glomerular filtration rate [eGFR] at screening, calculated by the central laboratory greater than 30 mL/min/1.73 m\^ 2) or on chronic dialysis
  • Use of erythropoietin or other haematopoietic growth factor treatment within 28 days of starting study treatment or anticipated need for such agents during the study
  • Participants who are not taking or are unable to take antimalarial prophylaxis at the time of consent and during the study if they live in areas of endemic malaria where prophylaxis is recommended
  • Travelled distance on standardized 6MWT below 100m at screening

Where in United States

Also in 20 other countries, 115 sites

  • Children's Healthcare AtlantaAtlanta, United StatesContact: Novo NordiskTaking people
  • Clinical and Transl Res CenterAurora, United StatesContact: Novo NordiskNo longer taking part
  • Uni of Alabama at BirminghamBirmingham, United StatesContact: Novo NordiskTaking people
  • Boston Children's HospitalBoston, United StatesContact: Novo NordiskTaking people
  • Boston Medical CenterBoston, United StatesContact: Novo NordiskTaking people
  • Interfaith Medical CenterBrooklyn, United StatesContact: Novo NordiskTaking people
  • NYC Health+HospitalsBrooklyn, United StatesContact: Novo NordiskTaking people
  • Childrens Hospital of ChicagoChicago, United StatesContact: Novo NordiskTaking people
  • Univer Of Illinois at ChicagoChicago, United StatesContact: Novo NordiskTaking people
  • Univ Hosp Cleveland Med CtrCleveland, United StatesContact: Novo NordiskTaking people
  • Ohio State Univ Wexner Med CtrColumbus, United StatesContact: Novo NordiskTaking people
  • Henry Ford Hospital_DetroitDetroit, United StatesContact: Novo NordiskNo longer taking part
  • Duke Comprehen Sickle CellDurham, United StatesContact: Novo NordiskTaking people
  • Duke University Medical CenterDurham, United StatesContact: Novo NordiskTaking people
  • Inova Health SystemFairfax, United StatesContact: Novo NordiskTaking people
  • East Carolina Univ-GreenvilleGreenville, United StatesContact: Novo NordiskTaking people
  • Memorial HealthcareHollywood, United StatesContact: Novo NordiskTaking people
  • UT Health University of TexasHouston, United StatesContact: Novo NordiskTaking people
  • Cure 4 the Kids FoundationLas Vegas, United StatesContact: Novo NordiskNo longer taking part
  • Arkansas Children's HospitalLittle Rock, United StatesContact: Novo NordiskTaking people
  • Children's Hospital Los Angeles - EndocrinologyLos Angeles, United StatesContact: Novo NordiskTaking people
  • UCLA HealthLos Angeles, United StatesContact: Novo NordiskNo longer taking part
  • Valley Children's HospitalMadera, United StatesContact: Novo NordiskTaking people
  • St. Jude Children's Res HospMemphis, United StatesContact: Novo NordiskTaking people
  • University of Tennessee Health Science CenterMemphis, United StatesContact: Novo NordiskTaking people
  • University of MinnesotaMinneapolis, United StatesContact: Novo NordiskTaking people
  • Univer South Alabama Ped/OncMobile, United StatesContact: Novo NordiskTaking people
  • Northwell HealthMount Kisco, United StatesContact: Novo NordiskNo longer taking part
  • Children's Hosp-New OrleansNew Orleans, United StatesContact: Novo NordiskTaking people
  • Newark Beth Israel MCNewark, United StatesContact: Novo NordiskTaking people
  • Children's Hsptl Of The KingsNorfolk, United StatesContact: Novo NordiskTaking people
  • Univ of OK Health Sciences CtrOklahoma City, United StatesContact: Novo NordiskTaking people
  • Children's NebraskaOmaha, United StatesContact: Novo NordiskTaking people
  • University of California IrvineOrange, United StatesContact: Novo NordiskNo longer taking part
  • Stanford University_Palo AltoPalo Alto, United StatesContact: Novo NordiskTaking people
  • Children's Hosptl PhiladelphiaPhiladelphia, United StatesContact: Novo NordiskTaking people
  • St Christopher Hosp for ChildPhiladelphia, United StatesContact: Novo NordiskTaking people
  • Phoenix Children's HsptlPhoenix, United StatesContact: Novo NordiskTaking people
  • Cohen Children's Medical CtrQueens, United StatesContact: Novo NordiskTaking people
  • Virginia Comm Univ Medical CtrRichmond, United StatesContact: Novo NordiskTaking people
  • Washington University St. LouisSt Louis, United StatesContact: Novo NordiskTaking people
  • Mary Bridge Children's HealthTacoma, United StatesContact: Novo NordiskTaking people
  • Jacobi Medical CenterThe Bronx, United StatesContact: Novo NordiskTaking people
  • Montefiore Medical CtrThe Bronx, United StatesContact: Novo NordiskTaking people
  • Harbor-UCLA Medical CenterTorrance, United StatesContact: Novo NordiskTaking people
  • Childrens National Medical CtrWashington D.C., United StatesContact: Novo NordiskTaking people
  • MedStar Hlth Res InstituteWashington D.C., United StatesContact: Novo NordiskTaking people
  • Nemours/AI duPont Hosp-ChldWilmington, United StatesContact: Novo NordiskTaking people
  • Atrium Health-Wake Forest BaptWinston-Salem, United StatesContact: Novo NordiskTaking people

About the trial

What the trial wants to find out

This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.

The 2 groups in the trial

  • EtavopivatTreatment being tested

    Participants will be randomised to receive oral dose of Etavopivat.

  • PlaceboPlacebo, for comparison

    Participants will be randomised to receive oral dose of placebo.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Global Phase 3, Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of Etavopivat in Adolescents and Adults With Sickle Cell Disease
Plain-language title
Testing Etavopivat for Pain Crises in Sickle Cell DiseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
17 September 2026